Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
23
06
2021
accepted:
26
11
2021
pubmed:
27
5
2022
medline:
2
8
2022
entrez:
26
5
2022
Statut:
epublish
Résumé
Rapid and reliable diagnostic work-up of tuberculosis (TB) remains a major healthcare goal. In particular, discrimination of TB infection from TB disease with currently available diagnostic tools is challenging and time consuming. This study aimed at establishing a standardised blood-based assay that rapidly and reliably discriminates TB infection from TB disease based on multiparameter analysis of TB antigen-reactive CD4 157 HIV-negative subjects with suspected TB infection or TB disease were recruited from local tertiary care hospitals in Berlin (Germany). Peripheral blood mononuclear cells were analysed for CD4 Using the scoring system, our assay (TB-Flow Assay) allowed reliable discrimination of TB infection from both pulmonary and extrapulmonary TB disease with high sensitivity (90.9%) and specificity (93.3%) as was confirmed by Monte-Carlo cross-validation. With low time requirement, ease of sample collection, and high sensitivity and specificity both for pulmonary and extrapulmonary TB disease, we believe this novel standardised TB-Flow Assay will improve the work-up of patients with suspected TB disease, supporting rapid TB diagnosis and facilitating treatment decisions.
Sections du résumé
BACKGROUND
Rapid and reliable diagnostic work-up of tuberculosis (TB) remains a major healthcare goal. In particular, discrimination of TB infection from TB disease with currently available diagnostic tools is challenging and time consuming. This study aimed at establishing a standardised blood-based assay that rapidly and reliably discriminates TB infection from TB disease based on multiparameter analysis of TB antigen-reactive CD4
METHODS
157 HIV-negative subjects with suspected TB infection or TB disease were recruited from local tertiary care hospitals in Berlin (Germany). Peripheral blood mononuclear cells were analysed for CD4
RESULTS
Using the scoring system, our assay (TB-Flow Assay) allowed reliable discrimination of TB infection from both pulmonary and extrapulmonary TB disease with high sensitivity (90.9%) and specificity (93.3%) as was confirmed by Monte-Carlo cross-validation.
CONCLUSION
With low time requirement, ease of sample collection, and high sensitivity and specificity both for pulmonary and extrapulmonary TB disease, we believe this novel standardised TB-Flow Assay will improve the work-up of patients with suspected TB disease, supporting rapid TB diagnosis and facilitating treatment decisions.
Identifiants
pubmed: 35618277
pii: 13993003.01780-2021
doi: 10.1183/13993003.01780-2021
pmc: PMC9329623
pii:
doi:
Substances chimiques
Antigens, Bacterial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©The authors 2022.
Déclaration de conflit d'intérêts
Conflict of interest: A. Scheffold and P. Bacher are advisors to Miltenyi Biotec who own IP rights on the use of CD154 for antigen-specific T-cell detection. A. Scheffold, C. Meisel, H-D. Volk, P. Bacher, T. Meyer and A. Mantei are listed as inventors in a patent (10 2018 131 696.8) that has been issued and a patent (PCT/EP2019/084392) that is pending on the discrimination of TB infection and TB disease using the method described herein. The remaining authors declare no competing financial interests.
Références
J Clin Invest. 2015 Sep;125(9):3723
pubmed: 26325038
BMC Public Health. 2008 Jan 14;8:15
pubmed: 18194573
Nat Med. 2005 Oct;11(10):1118-24
pubmed: 16186818
BMC Infect Dis. 2009 Jun 23;9:99
pubmed: 19549330
Eur J Immunol. 2013 Apr;43(4):939-48
pubmed: 23436562
Emerg Infect Dis. 2018 Mar;24(3):534-540
pubmed: 29460756
PLoS One. 2011 Mar 15;6(3):e17813
pubmed: 21423578
Dtsch Arztebl Int. 2019 Oct 25;116(43):729-735
pubmed: 31755407
Clin Microbiol Rev. 2018 Jul 18;31(4):
pubmed: 30021818
J Immunol. 2013 Apr 15;190(8):3967-76
pubmed: 23479226
Nat Rev Microbiol. 2009 Dec;7(12):845-55
pubmed: 19855401
Eur J Immunol. 2009 Mar;39(3):723-9
pubmed: 19224636
J Infect. 2015 Nov;71(5):526-33
pubmed: 26253021
Lancet. 2019 Sep 14;394(10202):967-978
pubmed: 31526740
Tuberc Respir Dis (Seoul). 2015 Apr;78(2):47-55
pubmed: 25861336
Nat Med. 2011 Mar;17(3):372-6
pubmed: 21336285
Am J Respir Crit Care Med. 2015 Feb 1;191(3):348-52
pubmed: 25635493
Front Immunol. 2018 Sep 28;9:2247
pubmed: 30323818
Front Immunol. 2017 Aug 10;8:968
pubmed: 28848561
BMC Infect Dis. 2018 Sep 10;18(1):457
pubmed: 30200884
Eur Respir J. 2011 Jan;37(1):100-11
pubmed: 20847080
Clin Infect Dis. 2020 Nov 5;71(8):1905-1911
pubmed: 31665254
Pulmonology. 2020 Nov - Dec;26(6):353-362
pubmed: 31843341
J Infect. 2020 Jul;81(1):57-71
pubmed: 32330526
Am J Respir Crit Care Med. 2016 Jun 1;193(11):1307-10
pubmed: 27248590
Front Immunol. 2018 Sep 19;9:2108
pubmed: 30283448
Pathogens. 2020 Mar 02;9(3):
pubmed: 32131556
Clin Immunol. 2015 Jul;159(1):37-46
pubmed: 25931385
Eur Respir J. 2018 Mar 22;51(3):
pubmed: 29567725
BMJ Open. 2014 Jun 10;4(6):e004818
pubmed: 24916087
Eur J Immunol. 2010 Aug;40(8):2211-20
pubmed: 20540114
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810